Logo image of LYEL

LYELL IMMUNOPHARMA INC (LYEL) Stock Fundamental Analysis

NASDAQ:LYEL - Nasdaq - US55083R1041 - Common Stock - Currency: USD

7.99  -0.23 (-2.8%)

Fundamental Rating

3

Taking everything into account, LYEL scores 3 out of 10 in our fundamental rating. LYEL was compared to 558 industry peers in the Biotechnology industry. LYEL has a great financial health rating, but its profitability evaluates not so good. LYEL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LYEL had negative earnings in the past year.
LYEL had a negative operating cash flow in the past year.
LYEL had negative earnings in each of the past 5 years.
LYEL had a negative operating cash flow in each of the past 5 years.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -77.83%, LYEL is doing worse than 69.71% of the companies in the same industry.
Looking at the Return On Equity, with a value of -99.41%, LYEL is in line with its industry, outperforming 45.88% of the companies in the same industry.
Industry RankSector Rank
ROA -77.83%
ROE -99.41%
ROIC N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LYEL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

8

2. Health

2.1 Basic Checks

LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LYEL has more shares outstanding
Compared to 5 years ago, LYEL has more shares outstanding
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 9.67 indicates that LYEL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.67, LYEL belongs to the best of the industry, outperforming 86.74% of the companies in the same industry.
LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.67
ROIC/WACCN/A
WACC9.53%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

LYEL has a Current Ratio of 7.49. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
LYEL's Current ratio of 7.49 is fine compared to the rest of the industry. LYEL outperforms 68.46% of its industry peers.
LYEL has a Quick Ratio of 7.49. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
LYEL's Quick ratio of 7.49 is fine compared to the rest of the industry. LYEL outperforms 68.82% of its industry peers.
Industry RankSector Rank
Current Ratio 7.49
Quick Ratio 7.49
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.59% over the past year.
LYEL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.47%.
The Revenue for LYEL have been decreasing by -37.89% on average. This is quite bad
EPS 1Y (TTM)7.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)-14.47%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%133.33%

3.2 Future

Based on estimates for the next years, LYEL will show a small growth in Earnings Per Share. The EPS will grow by 6.82% on average per year.
Based on estimates for the next years, LYEL will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y6.07%
EPS Next 2Y1.78%
EPS Next 3Y6.82%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LYEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LYEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.78%
EPS Next 3Y6.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LYEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (6/3/2025, 8:00:00 PM)

7.99

-0.23 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-07 2025-08-07
Inst Owners57.34%
Inst Owner Change1.42%
Ins Owners0.14%
Ins Owner Change2.32%
Market Cap2.36B
Analysts46.67
Price Target0.82 (-89.74%)
Short Float %N/A
Short Ratio14.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.69%
Min EPS beat(2)-15.34%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)4.3%
Min EPS beat(4)-15.34%
Max EPS beat(4)16.67%
EPS beat(8)6
Avg EPS beat(8)10.99%
EPS beat(12)10
Avg EPS beat(12)21.62%
EPS beat(16)12
Avg EPS beat(16)7.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)9.13%
EPS NQ rev (3m)19.23%
EPS NY rev (1m)1.36%
EPS NY rev (3m)-4.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36304.1
P/FCF N/A
P/OCF N/A
P/B 7.01
P/tB 7.01
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.83%
ROE -99.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 177.45%
Cap/Sales 49270.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.49
Quick Ratio 7.49
Altman-Z 9.67
F-Score3
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)103.35%
Cap/Depr(5y)398.19%
Cap/Sales(3y)18080.8%
Cap/Sales(5y)11104.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y6.07%
EPS Next 2Y1.78%
EPS Next 3Y6.82%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.47%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%133.33%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y7.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.07%
EBIT Next 3Y-7.28%
EBIT Next 5YN/A
FCF growth 1Y-12.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.29%
OCF growth 3YN/A
OCF growth 5YN/A